BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

328 related articles for article (PubMed ID: 22429723)

  • 1. In vitro activities of amphotericin B and AmBisome against Aspergillus isolates recovered from Italian patients treated for haematological malignancies.
    Colozza C; Posteraro B; Santilli S; De Carolis E; Sanguinetti M; Girmenia C
    Int J Antimicrob Agents; 2012 May; 39(5):440-3. PubMed ID: 22429723
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of the Sensititre YeastOne colorimetric antifungal panel and Etest with the NCCLS M38-A method to determine the activity of amphotericin B and itraconazole against clinical isolates of Aspergillus spp.
    Martín-Mazuelos E; Pemán J; Valverde A; Chaves M; Serrano MC; Cantón E
    J Antimicrob Chemother; 2003 Sep; 52(3):365-70. PubMed ID: 12917236
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of amphotericin B on Aspergillus flavus clinical isolates with variable susceptibilities to the polyene in an experimental model of systemic aspergillosis.
    Barchiesi F; Spreghini E; Sanguinetti M; Giannini D; Manso E; Castelli P; Girmenia C
    J Antimicrob Chemother; 2013 Nov; 68(11):2587-91. PubMed ID: 23794598
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular identification and amphotericin B susceptibility testing of clinical isolates of Aspergillus from 11 hospitals in Korea.
    Heo MS; Shin JH; Choi MJ; Park YJ; Lee HS; Koo SH; Lee WG; Kim SH; Shin MG; Suh SP; Ryang DW
    Ann Lab Med; 2015 Nov; 35(6):602-10. PubMed ID: 26354348
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased frequency of non-fumigatus Aspergillus species in amphotericin B- or triazole-pre-exposed cancer patients with positive cultures for aspergilli.
    Lionakis MS; Lewis RE; Torres HA; Albert ND; Raad II; Kontoyiannis DP
    Diagn Microbiol Infect Dis; 2005 May; 52(1):15-20. PubMed ID: 15878437
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Amphotericin B in vitro resistance is associated with fatal Aspergillus flavus infection.
    Hadrich I; Makni F; Neji S; Cheikhrouhou F; Bellaaj H; Elloumi M; Ayadi A; Ranque S
    Med Mycol; 2012 Nov; 50(8):829-34. PubMed ID: 22587728
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intrinsic in vitro susceptibility of primary clinical isolates of Aspergillus fumigatus, Aspergillus terreus, Aspergillus nidulans, Candida albicans and Candida lusitaniae against amphotericin B.
    Singh J; Rimek D; Kappe R
    Mycoses; 2006 Mar; 49(2):96-103. PubMed ID: 16466441
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro susceptibilities of Aspergillus spp. causing otomycosis to amphotericin B, voriconazole and itraconazole.
    Kaya AD; Kiraz N
    Mycoses; 2007 Nov; 50(6):447-50. PubMed ID: 17944704
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment failure in invasive aspergillosis: susceptibility of deep tissue isolates following treatment with amphotericin B.
    Paterson PJ; Seaton S; Prentice HG; Kibbler CC
    J Antimicrob Chemother; 2003 Nov; 52(5):873-6. PubMed ID: 14519673
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of clinical strains of Aspergillus terreus complex: molecular identification and antifungal susceptibility to azoles and amphotericin B.
    Escribano P; Peláez T; Recio S; Bouza E; Guinea J
    Clin Microbiol Infect; 2012 Feb; 18(2):E24-6. PubMed ID: 22128886
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro susceptibility testing of Candida and Aspergillus spp. to voriconazole and other antifungal agents using Etest: results of a French multicentre study.
    Mallié M; Bastide JM; Blancard A; Bonnin A; Bretagne S; Cambon M; Chandenier J; Chauveau V; Couprie B; Datry A; Feuilhade M; Grillot R; Guiguen C; Lavarde V; Letscher V; Linas MD; Michel A; Morin O; Paugam A; Piens MA; Raberin H; Tissot E; Toubas D; Wade A
    Int J Antimicrob Agents; 2005 Apr; 25(4):321-8. PubMed ID: 15784312
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative in vitro activities of posaconazole, voriconazole, itraconazole, and amphotericin B against Aspergillus and Rhizopus, and synergy testing for Rhizopus.
    Arikan S; Sancak B; Alp S; Hascelik G; McNicholas P
    Med Mycol; 2008 Sep; 46(6):567-73. PubMed ID: 19180726
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Survey of amphotericin B susceptibility of Candida clinical isolates determined by Etest.
    Chiu YS; Chang SC; Hsueh PR; Wang JL; Sun HY; Chen YC
    J Microbiol Immunol Infect; 2006 Aug; 39(4):335-41. PubMed ID: 16926981
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antifungal susceptibility of the aspergillus species by Etest and CLSI reference methods.
    Badiee P; Alborzi A; Moeini M; Haddadi P; Farshad S; Japoni A; Ziyaeyan M
    Arch Iran Med; 2012 Jul; 15(7):429-32. PubMed ID: 22724880
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [In vitro amphotericin B susceptibility of korean bloodstream yeast isolates assessed by the CLSI broth microdilution method, Etest, and Minimum fungicidal concentration test].
    Park JY; Shin JH; Uh Y; Kim EC; Kee SJ; Kim SH; Shin MG; Suh SP; Ryang DW
    Korean J Lab Med; 2008 Oct; 28(5):346-52. PubMed ID: 18971615
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Experimental pulmonary aspergillosis due to Aspergillus terreus: pathogenesis and treatment of an emerging fungal pathogen resistant to amphotericin B.
    Walsh TJ; Petraitis V; Petraitiene R; Field-Ridley A; Sutton D; Ghannoum M; Sein T; Schaufele R; Peter J; Bacher J; Casler H; Armstrong D; Espinel-Ingroff A; Rinaldi MG; Lyman CA
    J Infect Dis; 2003 Jul; 188(2):305-19. PubMed ID: 12854088
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro susceptibility of Candida species to five antifungal agents in a German university hospital assessed by the reference broth microdilution method and Etest.
    Fleck R; Dietz A; Hof H
    J Antimicrob Chemother; 2007 Apr; 59(4):767-71. PubMed ID: 17293369
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Water-soluble amphotericin B-polyvinylpyrrolidone complexes with maintained antifungal activity against Candida spp. and Aspergillus spp. and reduced haemolytic and cytotoxic effects.
    Charvalos E; Tzatzarakis MN; Van Bambeke F; Tulkens PM; Tsatsakis AM; Tzanakakis GN; Mingeot-Leclercq MP
    J Antimicrob Chemother; 2006 Feb; 57(2):236-44. PubMed ID: 16361329
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multicenter Study of Method-Dependent Epidemiological Cutoff Values for Detection of Resistance in Candida spp. and Aspergillus spp. to Amphotericin B and Echinocandins for the Etest Agar Diffusion Method.
    Espinel-Ingroff A; Arendrup M; Cantón E; Cordoba S; Dannaoui E; García-Rodríguez J; Gonzalez GM; Govender NP; Martin-Mazuelos E; Lackner M; Lass-Flörl C; Linares Sicilia MJ; Rodriguez-Iglesias MA; Pelaez T; Shields RK; Garcia-Effron G; Guinea J; Sanguinetti M; Turnidge J
    Antimicrob Agents Chemother; 2017 Jan; 61(1):. PubMed ID: 27799206
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antifungal susceptibilities of clinical isolates of Candida species, Cryptococcus neoformans, and Aspergillus species from Taiwan: surveillance of multicenter antimicrobial resistance in Taiwan program data from 2003.
    Hsueh PR; Lau YJ; Chuang YC; Wan JH; Huang WK; Shyr JM; Yan JJ; Yu KW; Wu JJ; Ko WC; Yang YC; Liu YC; Teng LJ; Liu CY; Luh KT
    Antimicrob Agents Chemother; 2005 Feb; 49(2):512-7. PubMed ID: 15673726
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.